Cancer Research and Treatment

Original Articles

Trends and Outcomes of Lung Cancer Surgery in South Korea: Joon Beom Park, Su-Jin Cho, Myung-Il Hahm, Danbee Kang, Seong Yong Park; Received March 14, 2025 Accepted May 11, 2025 Published online May 27, 2025; DOI: https://doi.org/10.4143/crt.2025.295 [Accepted]

Abstract PDF Supplementary Material: Purpose
This study analyzed nationwide trends in lung cancer surgery in South Korea over 14 years, focusing on surgical volume, patient demographics, surgical approaches, and outcomes.
Materials and Methods
We performed a retrospective cohort study using nationwide health insurance claims data (124,334 cases) and robotic surgery data (1,740 cases) provided by the manufacturer. Patients who underwent lung cancer surgery between 2010 and 2023 were included. Annual trends were assessed using the annual percentage change (APC), and logistic as well as linear regression models were used to identify predictors of mortality and prolonged hospital stay.
Results
The annual surgical volume increased from 4,557 in 2010 to 14,184 in 2023 (APC, 8.86%; p<0.001). Video-assisted thoracoscopic surgery (VATS) became the predominant approach, rising from 52.9% to 94.8% (APC, 4.11%; p<0.001). Sub-lobar resections increased, with wedge resections growing from 8.2% to 18.5% (APC, 5.72%; p<0.001) and segmentectomies from 4.2% to 9.6% (APC, 7.48%; p<0.001). The proportion of female patients increased from 32.0% to 44.7% (APC, 2.39%; p<0.001), while patients aged 70–79 years increased from 26.3% to 32.3% (APC, 1.60%; p<0.001) and those aged ≥80 years from 2.0% to 6.2% (APC, 9.63%; p<0.001). The median hospital stay decreased from 13 to 7 days (APC, -4.34%; p<0.001), and 30-day mortality declined from 2.45% to 0.76% (APC, -8.32%; p<0.001).
Conclusion
Lung cancer surgery in Korea has increased substantially, with a notable shift toward minimally invasive and lung-sparing techniques that have improved outcomes. However, persistent disparities underscore the need for a national surgical registry.

255 View
16 Download

Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide: Cheongin Yang, Changgon Kim, Kunye Kwak, Ka-Won Kang, Yong Park, Byung Soo Kim, Seong Hyun Jeong, Joon Seong Park, Yoon Seok Choi; Received April 17, 2025 Accepted April 24, 2025 Published online April 25, 2025; DOI: https://doi.org/10.4143/crt.2025.418 [Accepted]

Abstract PDF: Purpose
This retrospective study evaluated the efficacy and safety of a weekly carfilzomib, cyclophosphamide, and dexamethasone (KCd) regimen in patients with relapsed or refractory multiple myeloma (RRMM) who had been previously treated with both bortezomib- and lenalidomide-containing regimens.
Materials and Methods
We conducted a retrospective analysis of 33 patients with RRMM who received the KCd regimen between March 2020 and February 2024. All patients had prior exposure to both bortezomib and lenalidomide, and the majority (93.9%) were refractory to lenalidomide. Carfilzomib was administered once weekly at 70 mg/m² (after a step-up dose), along with oral cyclophosphamide and dexamethasone. Treatment response was assessed according to the International Myeloma Working Group (IMWG) criteria, and survival outcomes were analyzed.
Results
The overall response rate was 66.7%, including a complete response or better in 15.1% of patients and a very good partial response or better in 42.4%. With a median follow-up of 31.7 months, the median progression-free survival (PFS) was 13.5 months (95% CI, 11.47–15.53), while the median overall survival (OS) was not reached. The most common grade ≥3 adverse event was neutropenia (15.2%). Non-hematologic grade ≥3 toxicities were infrequent and manageable.
Conclusion
The weekly KCd regimen demonstrated encouraging efficacy and tolerability in a heavily pretreated RRMM population. These findings support its use as a feasible treatment option, particularly in patients refractory to lenalidomide.

604 View
87 Download

Gastrointestinal cancer

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma: Seong Yong Park, Hong Kwan Kim, Yeong Jeong Jeon, Junghee Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jae Il Zo; Cancer Res Treat. 2023;55(4):1231-1239. Published online April 24, 2023; DOI: https://doi.org/10.4143/crt.2022.1417

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the efficacy of adjuvant chemotherapy after neoadjuvant chemoradiotherapy (CCRTx) followed by surgery in patients with esophageal squamous cell carcinoma (ESCC).
Materials and Methods
We retrospectively analyzed the data from 382 patients who received neoadjuvant CCRTx and esophagectomy for ESCC between 2003 and 2018.
Results
This study included 357 (93.4%) men, and the years median patient age was 63 (range, 40 to 84 years). Overall, 69 patients (18.1%) received adjuvant chemotherapy, whereas 313 patients (81.9%) did not. The median follow-up period was 28.07 months (interquartile range, 15.50 to 62.59). The 5-year overall survival (OS) and disease-free survival were 47.1% and 42.6%, respectively. Adjuvant chemotherapy did not improve OS in all patients, but subgroup analysis revealed that adjuvant chemotherapy improved the 5-year OS in patients with ypT+N+ (24.8% vs. 29.9%, p=0.048), whereas the survival benefit of adjuvant chemotherapy was not observed in patients with ypT0N0, ypT+N0, or ypT0N+. Multivariable analysis revealed that ypStage and adjuvant chemotherapy (hazard ratio, 0.601; p=0.046) were associated with OS in patients with ypT+N+. Freedom from distant metastasis was marginally different according to the adjuvant chemotherapy (48.3% vs. 41.3%, p=0.141).
Conclusion
Adjuvant chemotherapy after neoadjuvant therapy followed by surgery reduces the distant metastasis in ypT+N+ ESCC patients, thereby improving the OS. The consideration could be given to administration of adjuvant chemotherapy to ypT+N+ ESCC patients with tolerable conditions.

Citations

Citations to this article as recorded by

Postoperative Adjuvant Therapy Benefits Non‐pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real‐World Study
Defeng Liu, Ao Liu, Longxiang Guo, Yi Li, Yuanlin Li, Yuxiang Chi, Haiqun Lin, Jinming Yu, Minghuan Li
Thoracic Cancer.2025;[Epub] CrossRef
Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study
Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Frontiers in Immunology.2024;[Epub] CrossRef
Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer
Ruiya Ma, Yoshinaga Okugawa, Tadanobu Shimura, Shinji Yamashita, Yuhki Sato, Chengzeng Yin, Ryo Uratani, Takahito Kitajima, Hiroki Imaoka, Mikio Kawamura, Yuhki Morimoto, Yoshiki Okita, Shigeyuki Yoshiyama, Masaki Ohi, Yuji Toiyama
Surgical Oncology.2024; 53: 102044. CrossRef
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen
Frontiers in Immunology.2024;[Epub] CrossRef

3,681 View
168 Download
7 Web of Science
4 Crossref

Hematologic malignancy

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404): Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(2):684-692. Published online January 2, 2023; DOI: https://doi.org/10.4143/crt.2022.1434

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by

Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
Journal of Cancer Research Updates.2024; 13: 1. CrossRef
Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
Bone Marrow Transplantation.2024; 59(6): 838. CrossRef
Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
Frontiers in Oncology.2023;[Epub] CrossRef
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
Clinical and Experimental Medicine.2023; 23(8): 4219. CrossRef

5,835 View
209 Download
3 Web of Science
4 Crossref

Lung and Thoracic cancer

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study: Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik; Cancer Res Treat. 2023;55(1):94-102. Published online June 9, 2022; DOI: https://doi.org/10.4143/crt.2022.290

Abstract PDF Supplementary Material PubReader ePub

Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by

Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
Radiotherapy and Oncology.2024; 193: 110123. CrossRef
A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
Sevcan Atay
Cancers.2023; 15(21): 5219. CrossRef

6,240 View
146 Download
3 Web of Science
2 Crossref

Hematologic malignancy

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts: Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022; DOI: https://doi.org/10.4143/crt.2022.008

Abstract PDF PubReader ePub

Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
Cancer Cell International.2025;[Epub] CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Research.2023; 58(4): 166. CrossRef
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef

8,198 View
369 Download
3 Web of Science
4 Crossref

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL): Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won; Cancer Res Treat. 2023;55(1):304-313. Published online March 30, 2022; DOI: https://doi.org/10.4143/crt.2022.004

Abstract PDF PubReader ePub

Purpose
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.
Materials and Methods
Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg/kg/day, intravenously) administered on days –7, –6, and –5, etoposide (400 mg/m² intravenously) on days –5 and –4, and melphalan (50 mg/m2/day intravenously) on days –3 and –2. The BuCE regimen was comprised of busulfan (3.2 mg/kg/day intravenously) on days –7, –6, and –5, etoposide (400 mg/m²/day intravenously) on days –5 and –4, and cyclophosphamide (50 mg/kg/day intravenously) on days –3 and –2. The primary endpoint was 2-year progression-free survival (PFS).
Results
Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.
Conclusion
There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.

Citations

Citations to this article as recorded by

Shorting of existing conditioning regimen for relapsed/refractory gastric diffuse large B-cell lymphoma transplant and studying its related outcomes: A first of its kind case report
Priyatesh Chandra Dwivedi, Yasam Venkata Ramesh, Raj Nagarkar
Iraqi Journal of Hematology.2025;[Epub] CrossRef
CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-match
Tao Wang, Ping Liu, Lili Xu, Lei Gao, Xiong Ni, Gusheng Tang, Li Chen, Jie Chen, Libing Wang, Yang Wang, Weijia Fu, Wenqin Yue, Na Liu, Ruobing Li, Guihua Lu, Yanrong Luo, Jianmin Yang
Annals of Hematology.2024; 103(2): 575. CrossRef

6,206 View
238 Download
2 Web of Science
2 Crossref

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study: Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021; DOI: https://doi.org/10.4143/crt.2021.1168

Abstract PDF Supplementary Material PubReader ePub

Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.

Citations

Citations to this article as recorded by

Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia
Se-Il Go, Eun-Jeong Jeong, Woo Je Lee, Sungwoo Park, Mi Jung Park, Gyeong-Won Lee
Supportive Care in Cancer.2025;[Epub] CrossRef

8,223 View
304 Download
2 Web of Science
1 Crossref

Breast cancer

Evaluation of a Direct Reverse Transcription Loop-Mediated Isothermal Amplification Method without RNA Extraction (Direct RT-LAMP) for the Detection of Lymph Node Metastasis in Early Breast Cancer: In Hee Lee, Jin Hyang Jung, Soo Jung Lee, Jeeyeon Lee, Ho Yong Park, Ji-Young Park, Jee Young Park, Jae-hwan Jung, Hyunchul Lee, Hyo-Sung Jeon, Yee Soo Chae; Cancer Res Treat. 2022;54(1):174-181. Published online April 26, 2021; DOI: https://doi.org/10.4143/crt.2020.749

Abstract PDF Supplementary Material PubReader ePub

Purpose
Assessing lymph node metastasis, tumor-derived DNA, or tumor-derived RNA has previously been studied in place of immunohistochemical assay. Because a direct reverse transcription loop-mediated isothermal amplification method (direct RT-LAMP) has been previously developed in order to rapidly identify viruses in place of RNA extraction, our team hypothesized that a direct RT-LAMP assay can be employed as a substitute in order to detect tumor involvement of lymph nodes within breast cancer patients.
Materials and Methods
A total amount of 92 lymph nodes removed across 40 patients possessing breast cancer were collected at Kyungpook National University Chilgok Hospital between the months of November 2015 and February 2016. All samples were then evaluated and contrasted via both a direct RT-LAMP assay and routine histopathologic examination.
Results
The sensitivity and specificity of the direct RT-LAMP assay were 85.7% and 100%, respectively. The positive predictive value and negative predictive value were 100% and 94.4%, respectively.
Conclusion
Direct RT-LAMP assay is capable of facilitating the detection of sentinel lymph node metastasis within breast cancer patients intraoperatively possessing an excellent sensitivity via a cost-effective and time-saving manner.

Citations

Citations to this article as recorded by

Development and evaluation of an easy to use real-time reverse-transcription loop-mediated isothermal amplification assay for clinical diagnosis of West Nile virus
Marwa Khedhiri, Melek Chaouch, Kaouther Ayouni, Anissa Chouikha, Mariem Gdoura, Henda Touzi, Nahed Hogga, Alia Benkahla, Wasfi Fares, Henda Triki
Journal of Clinical Virology.2024; 170: 105633. CrossRef
Versatility of reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) from diagnosis of early pathological infection to mutation detection in organisms
Srishti Sen, Priyanka Bhowmik, Shubhangi Tiwari, Yoav Peleg, Boudhayan Bandyopadhyay
Molecular Biology Reports.2024;[Epub] CrossRef

7,371 View
227 Download
2 Web of Science
2 Crossref

Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma: Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh, On behalf of the Consortium for Improving Survival of Lymphoma investigators; Cancer Res Treat. 2019;51(4):1302-1312. Published online February 14, 2019; DOI: https://doi.org/10.4143/crt.2018.555

Abstract PDF PubReader ePub

Purpose
Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.
Materials and Methods
We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.
Results
Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.
Conclusion
PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

Citations

Citations to this article as recorded by

Space-associated lymphomas: review of a heterogeneous group of old and new entities
Judith A Ferry
Diagnostic Histopathology.2024; 30(8): 430. CrossRef
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients
Julien Calvani, Laurence Gérard, Jehane Fadlallah, Elsa Poullot, Lionel Galicier, Cyrielle Robe, Margaux Garzaro, Remi Bertinchamp, David Boutboul, Wendy Cuccuini, Jean-Michel Cayuela, Philippe Gaulard, Éric Oksenhendler, Véronique Meignin
American Journal of Surgical Pathology.2022; 46(3): 353. CrossRef
A Rapidly Accumulating Effusion in an Immunocompetent Woman
Zein Kattih, Akhilesh Mahajan, Morana Vojnic, Jordan Steinberg, Alyssa Yurovitsky, Jin Ah Kim, Amory Novoselac
Chest.2022; 161(6): e377. CrossRef
Human herpesvirus‐8–positive primary effusion lymphoma in HIV‐negative patients: Single institution case series with a multidisciplinary characterization
Giovanni Rossi, Ilaria Cozzi, Irene Della Starza, Lucia Anna De Novi, Maria Stefania De Propris, Aurelia Gaeta, Luigi Petrucci, Alessandro Pulsoni, Federica Pulvirenti, Valeria Ascoli
Cancer Cytopathology.2021; 129(1): 62. CrossRef
Primary effusion lymphoma in human immune deficiency (HIV)‐negative non‐organ transplant immunocompetent patients
Lisi Yuan, James R. Cook, Tarik M. Elsheikh
Diagnostic Cytopathology.2020; 48(4): 380. CrossRef
Clinicopathologic characteristics and survival of patients with primary effusion lymphoma
Cristian Aguilar, Caddie Laberiano, Brady Beltran, Cecilia Diaz, Alvaro Taype-Rondan, Jorge J. Castillo
Leukemia & Lymphoma.2020; 61(9): 2093. CrossRef

7,032 View
159 Download
6 Web of Science
6 Crossref

Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database: Jae Seung Lee, In Rae Cho, Hye Won Lee, Mi Young Jeon, Tae Seop Lim, Oidov Baatarkhuu, Do Young Kim, Kwang-Hyub Han, Jun Yong Park; Cancer Res Treat. 2019;51(4):1347-1356. Published online February 12, 2019; DOI: https://doi.org/10.4143/crt.2018.477

Abstract PDF Supplementary Material PubReader ePub

Purpose
Conditional survival estimates (CSE) can provide additional useful prognostic information on the period of survival after diagnosis, which helps in counseling patients with cancer on their individual prognoses. This study aimed to analyze conditional survival (CS) for hepatocellular carcinoma (HCC) using a Korean national registry.
Materials and Methods
Patients with HCC, registered in the Korean cancer registry database, were retrospectively reviewed. Overall survival (OS) was calculated using the Kaplan-Meier method. The 1-year CS at X year or month after diagnosis were calculated as CS1=OS_(X+1)/OS_(X). CS calculations were performed in each Barcelona Clinic Liver Cancer stage, after which patients at stage 0, A, and B underwent subgroup analysis using initial treatment methods.
Results
A total of 4,063 patients diagnosed with HCC from January 2008 to December 2010, and 2,721 who were diagnosed from January 2011 to December 2012, were separately reviewed. In 2008-2010, the 1-year CS of 1, 2, 3, 4, and 5-year survivors was 82.9%, 85.1%, 88.3%, 88.0%, and 88.6%, respectively. Patients demonstrated an increase in CSE over time in subgroup analysis, especially in the advanced stages. In 2011-2012, the 1-year CS of 6, 12, 18, 24, 30, and 36 months was 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%, respectively. The subgroup analysis showed the same tendency towards increased CSE in the advanced stages.
Conclusion
Overall, the CS improved with each additional year after diagnosis in both groups. CSE may therefore provide a more accurate prognosis and hopeful message to patients who are surviving with or after treatment.

Citations

Citations to this article as recorded by

Development and validation of a dynamic prognostic nomogram for conditional survival in hepatocellular carcinoma: an analysis from the Korea Liver Cancer Registry
Jae Hyun Kwon, Eun-Kyoung Jwa, Jong Woo Lee, Eunyoung Tak, Shin Hwang
Scientific Reports.2025;[Epub] CrossRef
Improving Hepatocellular Carcinoma Surveillance Outcomes in Patients with Cirrhosis after Hepatitis C Cure: A Modelling Study
Jacob Cumming, Nick Scott, Jessica Howell, Joan Ericka Flores, Damian Pavlyshyn, Margaret E. Hellard, Leon Shin-han Winata, Marno Ryan, Tom Sutherland, Alexander J. Thompson, Joseph S. Doyle, Rachel Sacks-Davis
Cancers.2024; 16(15): 2745. CrossRef
Analysis of conditional survival in primary hepatocellular carcinoma after narrow-margin hepatectomy: a large-sample, dual-centre, retrospective study
Jie Kong, Tingfeng Huang, Jianxi Zhang, Shichuan Tang, Hongzhi Liu, Jingfeng Liu, Yongyi Zeng
HPB.2023; 25(2): 179. CrossRef
Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
Frontiers in Oncology.2023;[Epub] CrossRef
Early diagnosis and prognosis of hepatocellular carcinoma based on a ceRNA array
Li-xin Wang, Ao-ran Kong, Hui Dong
Oncologie.2023; 25(3): 245. CrossRef
Conditional survival probability of distant-metastatic hepatocellular carcinoma: A population-based study
Yong-Ping Yang, Cheng-Jun Guo, Zhao-Xuan Gu, Jun-Jie Hua, Jia-Xuan Zhang, Jian Shi
World Journal of Gastrointestinal Oncology.2023; 15(11): 1874. CrossRef
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Hye Won Lee, Kyung Joo Cho, Jun Yong Park
Immune Network.2020;[Epub] CrossRef
Dynamic evaluation of conditional survival in patients with oral squamous cell carcinoma after surgical resection: A large-scale prospective study
Lingjun Yan, Fa Chen, Lin Chen, Jing Lin, Qing Chen, Xiaodan Bao, Yu Qiu, Lisong Lin, Xiaoyan Zheng, Lizhen Pan, Jing Wang, Zhijian Hu, Fengqiong Liu, Baochang He, Bin Shi
Oral Oncology.2020; 104: 104639. CrossRef
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
Jaewoong Kim, Jin Won Chang, Jun Yong Park
Journal of Liver Cancer.2020; 20(1): 72. CrossRef
Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park
Cancers.2019; 11(4): 509. CrossRef

7,803 View
141 Download
9 Web of Science
10 Crossref

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis: Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh; Cancer Res Treat. 2015;47(2):173-181. Published online October 28, 2014; DOI: https://doi.org/10.4143/crt.2014.055

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
Frontiers in Oncology.2022;[Epub] CrossRef
Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
Cancer Medicine.2019; 8(3): 874. CrossRef
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
Leukemia & Lymphoma.2019; 60(10): 2532. CrossRef
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
International Journal of Hematology.2018; 107(4): 395. CrossRef
Recent advances in treating extra-ocular lymphomas
Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
Expert Review of Ophthalmology.2018; 13(4): 205. CrossRef
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
Blood Research.2017; 52(1): 3. CrossRef
Primary lymphomas in the gastrointestinal tract
Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
Journal of Digestive Diseases.2015; 16(4): 169. CrossRef

16,247 View
147 Download
10 Web of Science
7 Crossref

Review Article

Systems Biology Approaches to Decoding the Genome of Liver Cancer: Ju-Seog Lee, Ji Hoon Kim, Yun-Yong Park, Gordon B. Mills; Cancer Res Treat. 2011;43(4):205-211. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.205

Abstract PDF PubReader ePub

Molecular classification of cancers has been significantly improved patient outcomes through the implementation of treatment protocols tailored to the abnormalities present in each patient's cancer cells. Breast cancer represents the poster child with marked improvements in outcome occurring due to the implementation of targeted therapies for estrogen receptor or human epidermal growth factor receptor-2 positive breast cancers. Important subtypes with characteristic molecular features as potential therapeutic targets are likely to exist for all tumor lineages including hepatocellular carcinoma (HCC) but have yet to be discovered and validated as targets. Because each tumor accumulates hundreds or thousands of genomic and epigenetic alterations of critical genes, it is challenging to identify and validate candidate tumor aberrations as therapeutic targets or biomarkers that predict prognosis or response to therapy. Therefore, there is an urgent need to devise new experimental and analytical strategies to overcome this problem. Systems biology approaches integrating multiple data sets and technologies analyzing patient tissues holds great promise for the identification of novel therapeutic targets and linked predictive biomarkers allowing implementation of personalized medicine for HCC patients.

Citations

Citations to this article as recorded by

Systems Challenges of Hepatic Carcinomas: A Review
Dhatri Madduru, Johny Ijaq, Sujata Dhar, Saumyadip Sarkar, Naresh Poondla, Partha S. Das, Silvia Vasquez, Prashanth Suravajhala
Journal of Clinical and Experimental Hepatology.2019; 9(2): 233. CrossRef
Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease
Yuan Tian, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Alfred Sze-Lok Cheng
Seminars in Cancer Biology.2013; 23(6): 471. CrossRef
The Impact of Network Medicine in Gastroenterology and Hepatology
György Baffy
Clinical Gastroenterology and Hepatology.2013; 11(10): 1240. CrossRef

10,464 View
64 Download
3 Crossref

Original Articles

Association of Single Nucleotide Polymorphisms in PIM-1 Gene with the Risk of Korean Lung Cancer: Dae Sik Kim, Jae Sook Sung, Eun Soon Shin, Jeong-Seon Ryu, In Keun Choi, Kyong Hwa Park, Yong Park, Eui Bae Kim, Seh Jong Park, Yeul Hong Kim; Cancer Res Treat. 2008;40(4):190-196. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.190

Abstract PDF PubReader ePub

Purpose

The expression of the PIM-1 gene, which is a proto-oncogene that encodes a serine/threonine kinase, is associated with multiple cellular functions such as proliferation, differentiation, apoptosis and tumorigenesis. In particular, several studies have reported that the PIM-1 gene is associated with the development of lymphoma, leukemia and prostate cancer. Therefore, this study was conducted to evaluate the association between the single nucleotide polymorphisms in the PIM-1 gene and the risk of lung cancer occurrence in the Korean population.

Materials and Methods

To evaluate the role of the PIM-1 gene in the development of lung cancer, the genotypes of the PIM-1 gene were determined in 408 lung cancer patients and 410 normal subjects.

Results

We found that the T-C-T-C haplotypes of the PIM-1 gene (-1196 T>C, IVS4 +55 T>C, IVS4 +1416 T>A and +3684 C>A) were associated with an increased risk of lung cancer [adjusted odds ratio (aOR): 3.98; 95% CI: 1.24~12.75, p-value: 0.020]. In particular, these haplotypes showed an increased risk of lung cancer in males (aOR: 5.67; 95% CI: 1.32~24.30, p-value: 0.019) and smokers (aOR: 7.82; 95% CI: 1.75~34.98, p-value: 0.007).

Conclusions

The present results suggest that the T-C-T-C haplotype of the PIM-1 gene could influence the risk of developing smoking-related lung cancer in the Korean population. Additional functional studies with an larger sample sized analysis are warranted to reconfirm our findings.

Citations

Citations to this article as recorded by

A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target
Ajaya Kumar Rout, Budheswar Dehury, Satya Narayan Parida, Sushree Swati Rout, Rajkumar Jena, Neha Kaushik, Nagendra Kumar Kaushik, Sukanta Kumar Pradhan, Chita Ranjan Sahoo, Ashok Kumar Singh, Meenakshi Arya, Bijay Kumar Behera
International Journal of Biological Macromolecules.2024; 270: 132030. CrossRef
Impact of Pim1 mutations on the survival outcomes of patients with breast cancer: Insights from a clinical study
Syed Sultan Beevi, Kavitha Anbrasu, Vinod Kumar Verma, Nagesh Kishan Panchal, Krishna Kiran Kannepalli, Raghu Ram Pillarisetti, Sailaja Madigubba, Jyotsana Dwivedi, Neha Damodar, Radhika Chowdary Darapuneni
Human Gene.2024; 40: 201295. CrossRef
HCG11 inhibits salivary adenoid cystic carcinoma by upregulating EphA2 via binding to miR-1297
Shujuan Yan, Meng Wang
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(2): 257. CrossRef
Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
Aanchal Rathi, Dhiraj Kumar, Gulam Mustafa Hasan, Mohammad Mahfuzul Haque, Md Imtaiyaz Hassan
Biochimica et Biophysica Acta (BBA) - General Subjects.2021; 1865(11): 129995. CrossRef
Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)
Jiajie Xu, Xin Zhu, Qingling Li, Chao Chen, Zhenying Guo, Zhuo Tan, Chuanming Zheng, Minghua Ge
Cancer Cell International.2018;[Epub] CrossRef
PIM Kinase as an Executional Target in Cancer
Xinning Zhang, Mengqiu Song, Joydeb Kumar Kundu, Mee-Hyun Lee, Zhen-Zhen Liu
Journal of Cancer Prevention.2018; 23(3): 109. CrossRef
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372
Jiahui An, Jie Xu, Jiao Li, Song Jia, Xiaonan Li, Yanan Lu, Yuxin Yang, Zhuojia Lin, Xiaoru Xin, Mengying Wu, Qidi Zheng, Hu Pu, Xin Gui, Tianming Li, Dongdong Lu
Oncotarget.2017; 8(30): 49093. CrossRef
Expressions of osteopontin (OPN), ανβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC)
Yi Jin, Da-yue Tong, Lu-ying Tang, Jian-ning Chen, Jing Zhou, Zhi-ying Feng, Chun-kui Shao
Chinese Journal of Cancer Research.2012; 24(2): 103. CrossRef
Overexpression of Osteopontin, αvβ3 and Pim-1 Associated with Prognostically Important Clinicopathologic Variables in Non-Small Cell Lung Cancer
Yi Jin, Da-yue Tong, Jian-ning Chen, Zhi-ying Feng, Jian-yong Yang, Chun-kui Shao, Jia-ping Li, Rossella Rota
PLoS ONE.2012; 7(10): e48575. CrossRef
No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population
Jae-Sook Sung, Kyong-Hwa Park, Seung-Tae Kim, Jae-Hong Seo, Sang-Won Shin, Jun-Suk Kim, Yeul-Hong Kim
Genomics & Informatics.2010; 8(4): 194. CrossRef

11,665 View
85 Download
10 Crossref

Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer: Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung; Cancer Res Treat. 2008;40(4):178-183. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.178

Abstract PDF PubReader ePub

Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by

Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer
Gabriela Rahnea-Nita, Alexandru Nechifor, Mihai-Teodor Georgescu, Dorel Firescu, Adrian-Cornel Maier, Radu-Valeriu Toma, Valentin Titus Grigorean, Liliana-Florina Andronache, Roxana-Andreea Rahnea-Nita, Ionut Simion Coman, Laura-Florentina Rebegea
Journal of Clinical Medicine.2025; 14(10): 3299. CrossRef
African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
Head & Neck.2022; 44(10): 2069. CrossRef
Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
World Journal of Nuclear Medicine.2021; 20(02): 164. CrossRef
Modern Radiology in the Management of Head and Neck Cancer
G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
Clinical Oncology.2016; 28(7): 440. CrossRef
Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
Journal of Craniofacial Surgery.2011; 22(1): 348. CrossRef

11,448 View
72 Download
5 Crossref

The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer: Yong Park, Jee Won Kim, Dae Sik Kim, Eui Bae Kim, Se Jong Park, Jin Yong Park, Woo Suk Choi, Jong Gyu Song, Hee Yun Seo, Sang Cheul Oh, Byung Soo Kim, Jong Jae Park, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2008;40(3):127-132. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.127

Abstract PDF PubReader ePub

Purpose

Bone Morphogenetic Proteins (BMPs) are members of the TGF-β superfamily and it has been demonstrated that BMPs enhance migration, invasion and metastasis. The purpose of this study was to identify the association between the serum BMP-2 level and the progression status of gastric cancer.

Materials and Methods

Fifty-five patients with metastatic gastric cancer (metastatic disease group), six patients with early gastric cancer without lymph node metastasis (the EGC group), and ten healthy control subjects were enrolled in this study. The serum BMP-2 level was quantified by use of a commercially available ELISA kit. In EGC group patients and patients with metastatic disease, whole blood was obtained before endoscopic mucosal resection and before the commencement of a scheduled cycle of systemic chemotherapy, respectively.

Results

No significant difference in the mean serum BMP-2 levels was observed between the control subjects and the EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p=1.0). However, the metastatic disease group patients had a significantly higher level of serum BMP (179.61 pg/ml) than the control subjects and EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p<0.0001). Moreover, the mean serum BMP-2 level from patients with a bone metastasis was significantly higher than the mean serum BMP-2 level from patients without a bone metastasis (204.73 pg/ml versus 173.33 pg/ml, p=0.021).

Conclusions

BMP-2 seems to have a role in progression to metastatic disease in gastric cancer, especially in the late stage of tumorigenesis, including invasion and metastasis. BMP-2 may facilitate bone metastasis in gastric cancer. To confirm these findings, further studies are required with tissue specimens and the use of a cancer cell line.

Citations

Citations to this article as recorded by

Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis—A Pilot Prospective Observational Cohort Study
Lazar Chisavu, Viviana Mihaela Ivan, Adelina Mihaescu, Flavia Chisavu, Oana Schiller, Luciana Marc, Flaviu Bob, Adalbert Schiller
Diagnostics.2024; 14(6): 664. CrossRef
Duality of bone morphogenetic proteins in cancer: A comprehensive analysis
Tanu Sharma, Anmol Kapoor, Chandi C. Mandal
Journal of Cellular Physiology.2022; 237(8): 3127. CrossRef
BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer
Zilu Chen, Liyue Yuan, Xiaopeng Li, Junhui Yu, Zhengshui Xu
Cell Cycle.2022; 21(21): 2298. CrossRef
Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour
Alejandro Álvarez-Artime, Belén García-Soler, Rosa María Sainz, Juan Carlos Mayo
International Journal of Molecular Sciences.2021; 22(11): 5560. CrossRef
Magnesium ions regulate mesenchymal stem cells population and osteogenic differentiation: A fuzzy agent-based modeling approach
Jalil Nourisa, Berit Zeller-Plumhoff, Heike Helmholz, Bérengère Luthringer-Feyerabend, Vladimir Ivannikov, Regine Willumeit-Römer
Computational and Structural Biotechnology Journal.2021; 19: 4110. CrossRef
BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract
Yongchun Zhang, Jianwen Que
Annual Review of Physiology.2020; 82(1): 251. CrossRef
Relaxin enhances bone regeneration with BMP‐2‐loaded hydroxyapatite microspheres
Sahitya Injamuri, Mohamed N. Rahaman, Youqu Shen, Yue‐Wern Huang
Journal of Biomedical Materials Research Part A.2020; 108(5): 1231. CrossRef
Annatto-Derived Tocotrienol Promotes Mineralization of MC3T3-E1 Cells by Enhancing BMP-2 Protein Expression via Inhibiting RhoA Activation and HMG-CoA Reductase Gene Expression

Wan Nuraini Wan Hasan, Kok-Yong Chin, Norzana Abd Ghafar, Ima Nirwana Soelaiman
Drug Design, Development and Therapy.2020; Volume 14: 969. CrossRef
Detection of circulating BMP5 as a risk factor for Barrett’s esophagus
Ana C. P. Correia, Silvia Calpe, Nahid Mostafavi, Sanne Johanna Maria Hoefnagel, Maria del Carmen Sancho-Serra, Patricia S. de Koning, Kausilia K. Krishnadath
Scientific Reports.2020;[Epub] CrossRef
The Dual Role of Bone Morphogenetic Proteins in Cancer
Duc-Hiep Bach, Hyen Joo Park, Sang Kook Lee
Molecular Therapy - Oncolytics.2018; 8: 1. CrossRef
Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
Tobias Sinnberg, Heike Niessner, Mitch P. Levesque, Christoph Dettweiler, Claus Garbe, Christian Busch
Biology Open.2018;[Epub] CrossRef
Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis
Bum Sik Tae, Seok Cho, Hyun Cheol Kim, Cheol Hwan Kim, Seok Ho Kang, Jeong Gu Lee, Je Jong Kim, Hong Seok Park, Jun Cheon, Mi Mi Oh, Sung Gu Kang
Scientific Reports.2018;[Epub] CrossRef
Computational model of mesenchymal migration in 3D under chemotaxis
F. O. Ribeiro, M. J. Gómez-Benito, J. Folgado, P. R. Fernandes, J. M. García-Aznar
Computer Methods in Biomechanics and Biomedical Engineering.2017; 20(1): 59. CrossRef
Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy
Haijun Tian, Jie Zhao, Elsa J. Brochmann, Jeffrey C. Wang, Samuel S. Murray
Cytokine & Growth Factor Reviews.2017; 34: 73. CrossRef
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells
Min Hu, Facai Cui, Fengzhen Liu, Jinlin Wang, Xiaoxia Wei, Yi Li
International Journal of Oncology.2017; 50(1): 193. CrossRef
Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis
Jian Sun, Xuan Liu, Hong Gao, Long Zhang, Qing Ji, Ziyuan Wang, Lihong Zhou, Yan Wang, Hua Sui, Zhongze Fan, Qi Li
Oncotarget.2017; 8(7): 11489. CrossRef
BMP10 inhibited the growth and migration of gastric cancer cells
Haiming Lei, Jian Wang, Peihua Lu, Xinghua Si, Koulan Han, Tingyan Ruan, Junjie Lu
Tumor Biology.2016; 37(3): 3025. CrossRef
How does the pathophysiological context influence delivery of bone growth factors?
Xiaohua Yu, Darilis Suárez-González, Andrew S. Khalil, William L. Murphy
Advanced Drug Delivery Reviews.2015; 84: 68. CrossRef
Inactivation of the Phosphatidylinositol 3‐Kinase/Akt Pathway is Involved in BMP9‐mediated Tumor‐suppressive Effects in Gastric Cancer Cells
Liang Duan, Liwei Ye, Rui Wu, Haiyan Wang, Xueru Li, Huan Li, Shimei Yuan, He Zha, Hui Sun, Yunyuan Zhang, Xian Chen, Yan Zhang, Lan Zhou
Journal of Cellular Biochemistry.2015; 116(6): 1080. CrossRef
Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2
Yun-Jung Choi, Patrick N. Ingram, Kun Yang, Lan Coffman, Mangala Iyengar, Shoumei Bai, Dafydd G. Thomas, Euisik Yoon, Ronald J. Buckanovich
Proceedings of the National Academy of Sciences.2015;[Epub] CrossRef
Association Between BMP-2 and Carcinogenicity
Branko Skovrlj, Steven M. Koehler, Paul A. Anderson, Sheeraz A. Qureshi, Andrew C. Hecht, James C. Iatridis, Samuel K. Cho
SPINE.2015; 40(23): 1862. CrossRef
In silico Mechano-Chemical Model of Bone Healing for the Regeneration of Critical Defects: The Effect of BMP-2
Frederico O. Ribeiro, María José Gómez-Benito, João Folgado, Paulo R. Fernandes, José Manuel García-Aznar, Masaya Yamamoto
PLOS ONE.2015; 10(6): e0127722. CrossRef
Comparative transcriptome analysis between metastatic and non-metastatic gastric cancer reveals potential biomarkers
DAN FENG, XIAOFEI YE, ZHENXIN ZHU, ZIRAN WEI, QINGPING CAI, YAJIE WANG
Molecular Medicine Reports.2015; 11(1): 386. CrossRef
Gastric stem cells and gastric cancer stem cells
Myoung-Eun Han, Sae-Ock Oh
Anatomy & Cell Biology.2013; 46(1): 8. CrossRef
Cancer stem cells: the ‘heartbeat’ of gastric cancer
Guihua Xu, Jie Shen, Xiaohui Ou Yang, Masakiyo Sasahara, Xiulan Su
Journal of Gastroenterology.2013; 48(7): 781. CrossRef
Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients
Zheng-Hua Fei, Cheng-Yun Yao, Xiao-Lei Yang, Xin-En Huang, Sheng-Lin Ma
Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5293. CrossRef
P‐glycoprotein (ABCB1) inhibited network of mitochondrion transport along microtubule and BMP signal‐induced cell shape in chimpanzee left cerebrum by systems‐theoretical analysis
Hong Lin, Lin Wang, Minghu Jiang, Juxiang Huang, Lianxiu Qi
Cell Biochemistry and Function.2012; 30(7): 582. CrossRef
Bone–vasculature interactions in the mandible: Is bone an angiogenic tissue?
E.M. Dietrich, K. Antoniades
Medical Hypotheses.2012; 79(5): 582. CrossRef
Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients
Elísio Costa, Joana Coimbra, Cristina Catarino, Sandra Ribeiro, Flávio Reis, Henrique Nascimento, João Fernandes, Vasco Miranda, Maria do Sameiro Faria, Luís Belo, Alice Santos-Silva
Renal Failure.2012; 34(10): 1355. CrossRef
Bone Morphogenetic Protein-4-induced Epithelial-Mesenchymal Transition and Invasiveness Through Smad1-mediated Signal Pathway in Squamous Cell Carcinoma of the Head and Neck
Ting Xu, Chang-yun Yu, Jin-jie Sun, Yong Liu, Xing-wei Wang, Lei-ming Pi, Yong-quan Tian, Xin Zhang
Archives of Medical Research.2011; 42(2): 128. CrossRef
Bone Morphogenetic Protein-2 and -4 Play Tumor Suppressive Roles in Human Diffuse-Type Gastric Carcinoma
Yo-taro Shirai, Shogo Ehata, Masakazu Yashiro, Kazuyoshi Yanagihara, Kosei Hirakawa, Kohei Miyazono
The American Journal of Pathology.2011; 179(6): 2920. CrossRef
Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression
Myoung Hee Kang, Sang Cheul Oh, Hyun Joo Lee, Han Na Kang, Jung Lim Kim, Jun Suk Kim, Young A. Yoo
Experimental Cell Research.2011; 317(12): 1746. CrossRef
Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma
Ulrike Maegdefrau, Stephanie Arndt, Georgi Kivorski, Claus Hellerbrand, Anja-Katrin Bosserhoff
Laboratory Investigation.2011; 91(11): 1615. CrossRef
Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy
JIN-SOON SUH, WON-HO HAHN, JONG SEOK LEE, HAE JEONG PARK, MI-JA KIM, SUNG WOOK KANG, JOO-HO CHUNG, BYOUNG-SOO CHO
Experimental and Therapeutic Medicine.2011; 2(2): 337. CrossRef
Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression
Yong Park, Myoung Hee Kang, Hee Yeon Seo, Joong Min Park, Chul Won Choi, Yeul Hong Kim, In Sun Kim, Jun Suk Kim, Sang Cheul Oh
Medical Oncology.2010; 27(4): 1192. CrossRef
The Yin and Yang of bone morphogenetic proteins in cancer
Ashok Singh, Rebecca J. Morris
Cytokine & Growth Factor Reviews.2010; 21(4): 299. CrossRef
BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
Myoung Hee Kang, Jun Suk Kim, Ji Eun Seo, Sang Cheul Oh, Young A. Yoo
Experimental Cell Research.2010; 316(1): 24. CrossRef

12,454 View
76 Download
37 Crossref

Case Report

Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy: Eui Bae Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Kyoung Ho Rho, Seok Jin Kim; Cancer Res Treat. 2008;40(1):36-38. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.36

Abstract PDF PubReader ePub

Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.

Citations

Citations to this article as recorded by

Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens
Rui Lu, Meng Zhang, Zi-Han Liu, Miao Hao, Yan Tian, Mei Li, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Zi-Cheng Jiang, Xue-Mei Li, Guang-Hua Xu, Ya-Ping Li, Shuang-Suo Dang
World Journal of Gastroenterology.2024; 30(44): 4725. CrossRef
Very late-onset hepatitis B reactivation following chemoimmunotherapy
Edward R. Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg
Leukemia & Lymphoma.2022; 63(4): 991. CrossRef
Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients
Jieni Yu, Zhiqiang Xu, Yuanyuan Zhuo, Huahua Wei, Yinhai Ye, Qinhong Xu, Youli Li, Lihong Yu, Weiying Feng, Pan Hong, Kejie Zhang
Hematology.2021; 26(1): 956. CrossRef
Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency
Masako Hatano, Toshihide Mimura, Akira Shimada, Mitsuhiko Noda, Shigehiro Katayama
Endocrinology, Diabetes & Metabolism.2019;[Epub] CrossRef
Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen
Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano
Leukemia & Lymphoma.2015; 56(4): 1160. CrossRef
Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
Jesse Civan, Hie Won Hann
Expert Opinion on Drug Safety.2015; 14(6): 865. CrossRef
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy
Mauro Viganò, Giampaolo Mangia, Pietro Lampertico
Expert Opinion on Biological Therapy.2014; 14(7): 1019. CrossRef
A Case of Reactivation of Hepatitis B and Fulminant Hepatitis which developed 3 months following Chemotherapy Including Rituximab in a Patient with Lymphoma
Tae Won Lim, Hee Taek Oh, Seung Un Song, Hae Won Lee, Ji Yeon Kim, Seon Ja Park
Kosin Medical Journal.2014; 29(2): 161. CrossRef
Occult Hepatitis B Virus Infection: Transmission and Reactivation
Sang Hee Song, Seong Gyu Hwang
The Korean Journal of Gastroenterology.2013; 62(3): 148. CrossRef
Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma
Seung Jun Jang, Young Kul Jung, Hae Lim Baek, Hyun Hwa Yoon, Seung Kak Shin, Jun Shik Hong, Jin Ny Park, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Jae Hoon Lee, Ju Hyun Kim
Korean Journal of Medicine.2013; 85(6): 598. CrossRef
Occult Hepatitis B: Clinical Viewpoint and Management
Mehdi Zobeiri
Hepatitis Research and Treatment.2013; 2013: 1. CrossRef
Highly Sensitive Detection of Hepatitis B Virus Surface Antigen by Use of a Semiautomated Immune Complex Transfer Chemiluminescence Enzyme Immunoassay
Kazuhiko Takeda, Mari Maruki, Takahiro Yamagaito, Machiko Muramatsu, Yasuhiro Sakai, Hiroaki Tobimatsu, Hironori Kobayashi, Yoshiteru Mizuno, Yukio Hamaguchi
Journal of Clinical Microbiology.2013; 51(7): 2238. CrossRef
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami
Journal of Gastroenterology.2011; 46(1): 9. CrossRef
Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
Seong Min Chung, Joo Hyun Sohn, Tae Yeob Kim, Ki Deok Yoo, Yong Woo Ahn, Joong Ho Bae, Yong Cheol Jeon, Jung Hye Choi
The Korean Journal of Gastroenterology.2010; 55(4): 266. CrossRef
Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino
Medical Oncology.2010; 27(3): 912. CrossRef

14,699 View
91 Download
15 Crossref

Original Articles

Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue: Yoon Seok Choi, Seok Jin Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Hye Jin Shin, Kwang-Yoon Jung, Seung-Kuk Baek, Bong Kyung Shin, Jung Woo Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2007;39(3):109-115. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.109

Abstract PDF PubReader ePub

Purpose

Tumor cells are known to express hypoxia-related proteins such as glucose transporter-1 (Glut-1). These hypoxia-induced changes may allow tumor cells to survive under sustained hypoxic microenvironments, and the surviving tumor cell under hypoxia may develop a more aggressive phenotype and so result in a poor prognosis.

Materials and Methods

The Glut-1 expression was analyzed by immunohistochemistry, and its association with the prognosis was assessed in 60 patients with squamous cell carcinoma of the tongue.

Results

The Glut-1 expression was diffuse with a membranous pattern, and the median percentage of Glut-1 positive tumor cells was 60% (range: 0.0~90.0%). A high Glut-1 expression (the percentage of positive tumor cells ≥ the median value, 60%) was associated with the location of primary lesion, lymph node metastasis status and disease stage (p<0.05). The expression of Glut-1 was correlated with the Ki-67 expression (r=0.406, p=0.001). Microvessel density, as represented by CD31 staining, was also correlated with the Glut-1 expression although its significance is weak (r=0.267, p=0.039). On the univariate analysis, the group with a high Glut-1 expression showed poorer overall survival than the group with a low Glut-1 expression (p<0.05). However, the Glut-1 expression failed to show any independent prognostic significance on the multivariate analysis.

Conclusion

The expression of Glut-1 may be useful for predicting the prognosis and determining the treatment strategy for the management of squamous cell carcinoma of the tongue.

Citations

Citations to this article as recorded by

Study of expression of GLUT-1 in oral potentially malignant disorders and oral squamous cell carcinoma: An immuno-histochemical analysis
Shylaja K. Attur, Anil Patel, Kailash M. Attur
Journal of Oral and Maxillofacial Pathology.2024; 28(1): 70. CrossRef
Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis
Yanting Wang, Yuanyuan Li, Laibo Jiang, Xianyue Ren, Bin Cheng, Juan Xia
Aging.2021; 13(5): 7284. CrossRef
The Role of Glucose Transporters in Oral Squamous Cell Carcinoma
Heinrich Botha, Camile S. Farah, Kendrick Koo, Nicola Cirillo, Michael McCullough, Rita Paolini, Antonio Celentano
Biomolecules.2021; 11(8): 1070. CrossRef
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Angara Zambrano, Matías Molt, Elena Uribe, Mónica Salas
International Journal of Molecular Sciences.2019; 20(13): 3374. CrossRef
Can increased metabolic status be a grading tool for oral squamous cell carcinoma? A glucose transporter 1 immunoexpression study
Abikshyeet Panda, Alokenath Bandyopadhyay, Gouse Mohiddin, Malvika Raghuvanshi, SanjayKumar Sahoo, Lipsa Bhuyan
Nigerian Journal of Surgery.2019; 25(2): 203. CrossRef
Plumbagin‐mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma
S Na, J Zhang, X Zhou, A Tang, D Huang, Q Xu, D Xue, J Qiu
Oral Diseases.2018; 24(6): 920. CrossRef
Expression of GLUT-1 in oral squamous cell carcinoma in tobacco and non-tobacco users
Neha Azad, Malti Kumari Maurya, Meenakshi Kar, Madhu Mati Goel, Ajay Kumar Singh, Mala Sagar, Divya Mehrotra, Vijay Kumar
Journal of Oral Biology and Craniofacial Research.2016; 6(1): 25. CrossRef
Distribution of Hypoxia-Inducible Factor-1α and Glucose Transporter-1 in Human Tongue Cancers
Marcelo Gadelha Vasconcelos, Rodrigo Gadelha Vasconcelos, Denise Hélen Imaculada Pereira de Oliveira, Edilmar de Moura Santos, Leão Pereira Pinto, Éricka Janine Dantas da Silveira, Lélia Maria Guedes Queiroz
Journal of Oral and Maxillofacial Surgery.2015; 73(9): 1753. CrossRef
Expression of glucose transporters in cancers
Leszek Szablewski
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2013; 1835(2): 164. CrossRef
T-Type Ca2+Channels in Normal and Abnormal Brain Functions
Eunji Cheong, Hee-Sup Shin
Physiological Reviews.2013; 93(3): 961. CrossRef
Glucose uptake mediated by glucose transporter 1 is essential for early tooth morphogenesis and size determination of murine molars
Hiroko Ida-Yonemochi, Mitsushiro Nakatomi, Hidemitsu Harada, Hiroki Takata, Otto Baba, Hayato Ohshima
Developmental Biology.2012; 363(1): 52. CrossRef
Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary
Ja Seung Koo, Haeryoung Kim
Tumor Biology.2011; 32(5): 893. CrossRef

10,877 View
57 Download
12 Crossref

Evaluation of Parotid Gland Function following Intensity Modulated Radiation Therapy for Head and Neck Cancer: Seok Ho Lee, Tae Hyun Kim, Joo Young Kim, Sung Yong Park, Hong Ryull Pyo, Kyung Hwan Shin, Dae Yong Kim, Joo Young Kim, Kwan Ho Cho; Cancer Res Treat. 2006;38(2):84-91. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.84

Abstract PDF PubReader ePub

Purpose

This study was undertaken to determine the parotid gland tolerance dose levels following intensity modulated radiation therapy (IMRT) for treating patients who suffered with head and neck cancer.

Materials and Methods

From February 2003 through June 2004, 34 head and neck patients with 6 months of follow-up were evaluated for xerostomia after being treated by IMRT. Their median age was 59 years (range: 29~78). Xerostomia was assessed using a 4-question xerostomia questionnaire score (XQS) and a test for the salivary flow rates (unstimulated and stimulated: USFR and SSFR, respectively). The patients were also given a validated LENT SOMA scale (LSS) questionnaire. Evaluations were performed before IMRT and at 1, 3 and 6 months after IMRT.

Results

All 34 patients showed significant changes in the XQS, LSS and Salivary Flow rates (USFR and SSFR) after IMRT. No significant changes in the XQS or LSS were noted in 12 patients who received a total parotid mean dose of ≤3,100 cGy at 1, 3 and 6 months post-IMRT relative to the baseline values. However, for the 22 patients who received >3,100 cGy, significant increases in the XQS and LSS were observed. The USFR and SSFR from the parotid glands in 7 patients who received ≤2,750 cGy were significantly preserved at up to 6 months after IMRT. However, the USFR and SSFR in 27 patients who were treated with >2,750 cGy were significantly lower than the baseline values at all times after IMRT.

Conclusion

We suggest that the total parotid mean dose should be limited to ≤2,750 cGy to preserve the USFR and SSFR and so improve the subsequent quality of life.

Citations

Citations to this article as recorded by

Evaluation of the Effect of Photobiomodulation on Radiation-Induced Xerostomia in Head and Neck Cancer Patients: A Randomized Clinical Trial
Pegah Mosannen Mozaffari, Zahra Delavarian, Reza Fekrazad, Azar Fani Pakdel, Mahdokht Rashed Mohassel, Mohammad Taghi Shakeri, Ala Ghazi
Journal of Lasers in Medical Sciences.2024; 15: e4. CrossRef
Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
Marcell Costa de Medeiros, Stephanie The, Emily Bellile, Nickole Russo, Ligia Schmitd, Erika Danella, Priyanka Singh, Rajat Banerjee, Christine Bassis, George R. Murphy, Maureen A. Sartor, Isabelle Lombaert, Thomas M. Schmidt, Avi Eisbruch, Carol Anne Mur
Microbiome.2023;[Epub] CrossRef
Translation and cross-cultural adaption of the Chinese version of the Vanderbilt Head and Neck Symptom Survey version 2.0: a tool for oral symptom assessment in head and neck cancer patients
Min Jin, Li Sun, Rui Meng, Wenjing Wang, Rui Sun, Jing Huang, You Qin, Bian Wu, Qian Ding, Gang Peng, Tao Zhang, Kunyu Yang
Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Study of dosimetry and clinical factors for assessment of xerostomia in head and neck squamous cell carcinoma treated by intensity-modulated radiotherapy: A prospective study
Vrinda Singla, Vipul Nautiyal, Meenu Gupta, Viney Kumar, Shivani Mehra, Mushtaq Ahmad
Journal of Carcinogenesis.2021; 20(1): 14. CrossRef
Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis
Xiuhong Ge, Zhengluan Liao, Jianhua Yuan, Dewang Mao, Yumei Li, Enyan Yu, Xunheng Wang, Zhongxiang Ding
Supportive Care in Cancer.2020; 28(6): 2701. CrossRef
Xerostomia, salivary characteristics and gland volumes following intensity‐modulated radiotherapy for nasopharyngeal carcinoma: a two‐year follow up
CPC Sim, YL Soong, EPP Pang, C Lim, GD Walker, DJ Manton, EC Reynolds, JTS Wee
Australian Dental Journal.2018; 63(2): 217. CrossRef
Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease
L. Marangoni-Lopes, L.P. Rodrigues, R.H. Mendonça, M. Nobre-dos Santos
Archives of Oral Biology.2016; 72: 99. CrossRef
Is linac-based volumetric modulated arc therapy better than helical tomotherapy in the radiotherapy of nasopharyngeal carcinoma?
Vincent W. C. Wu, Bing-kin Choi, Ho-nam Chan, Ruby Lam, Yu-king Wong, Alan W. L. Mui, George Chiu
Journal of Radiation Oncology.2015; 4(1): 29. CrossRef
Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers: A Triple-Blind, Randomized, Placebo-Controlled Trial
Abbas Javadzadeh Bolouri, Atessa Pakfetrat, Arghavan Tonkaboni, Seyed Amir Aledavood, Mohsen Fathi Najafi, Zahra Delavarian, Mohammad Taghi Shakeri, Azade Mohtashami
Iranian Journal of Cancer Prevention.2015;[Epub] CrossRef
Evaluation of an automated knowledge based treatment planning system for head and neck
Jerome Krayenbuehl, Ian Norton, Gabriela Studer, Matthias Guckenberger
Radiation Oncology.2015;[Epub] CrossRef
Translation and validation of the Chinese version of the quality of life radiation therapy instrument and the head & neck module (QOL-RTI/H&N)
Xin-lin Chen, Zhen-wen Qiu, Mo-fa Gu, Yong Su, Li-zhi Liu, Yan Liu, Chuan-wei Mo, Qian Xu, Juan Sun, Dong-hai Li
Health and Quality of Life Outcomes.2014;[Epub] CrossRef
Correlation of Parotid Gland Function in Head and Neck Cancer Patients treated with Intensity-modulated Radiotherapy
Sonal Vahanwala, Sukhjinder Kaur Khosa, Sandeep S Pagare
International Journal of Head and Neck Surgery.2012; 3(1): 1. CrossRef
Effects of Intensity-modulated Radiotherapy on Human Oral Microflora
Zi-Yang SHAO, Zi-Sheng TANG, Chao YAN, Yun-Tao JIANG, Rui MA, Zheng LIU, Zheng-Wei HUANG
Journal of Radiation Research.2011; 52(6): 834. CrossRef

15,697 View
107 Download
13 Crossref

Resveratrol at High Doses Acts as an Apoptotic Inducer in Endothelial Cells: Kyungmin In, Jongbong Park, Heonyong Park; Cancer Res Treat. 2006;38(1):48-53. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.48

Abstract PDF PubReader ePub

Purposes

Resveratrol is a phenolic compound found in grapes and other food products. In order to assess the availability of resveratrol as an angio-inhibiting drug, we examined whether resveratrol plays an important role in bovine aortic endothelial cells (BAECs) for cell apoptosis and cell migration.

Methods and Materials

Endothelial cell apoptosis was observed as detected by the Hoechst staining and the caspase-3 activity. Additionally, Western blotting was performed for monitoring the activities of various cell signaling molecules.

Results

Resveratrol was shown to act as a pro-apoptotic agent. The pro-apoptotic effect of resveratrol was as great as that of etoposide, a well-known anti-cancer drug. In addition, resveratrol had an inhibitory effect on endothelial cell migration. The demonstrated efficacy of resveratrol suggests that resveratrol may be utilized as an anti-angiogenic drug. To determine the underlying mechanisms, we further investigated which signaling molecules are activated by resveratrol. Extracellular signal-regulated kinase (ERK) was activated by the treatment with resveratrol in BAECs, whereas endothelial nitric oxide synthetase (eNOS), Akt, and Jun N-terminal kinase (JNK) were inhibited. The pretreatment with PD compound, an ERK inhibitor, had no effect on the pro-apoptosis induced by resveratrol.

Conclusion

Resveratrol plays an important role in endothelial cell apoptosis, indicating that resveratrol can be utilized as a potent anti-angiogenic drug.

Citations

Citations to this article as recorded by

Novel plasma-polymerized coating facilitates HeLa cell spheroid formation, exerting necroptosis via β-cyclodextrin-encapsulated resveratrol
Sujeong Jang, Namwuk Baek, Youngsik Seo, Hyuna Lim, Donggeun Jung, Heonyong Park
Journal of Analytical Science and Technology.2024;[Epub] CrossRef
Effect of eIF2α in Neuronal Injury Induced by High Glucose and the Protective Mechanism of Resveratrol
Lijing Zhang, Kaining Zhi, Yanfang Su, Wenpeng Peng, Xianfang Meng
Molecular Neurobiology.2023; 60(10): 6043. CrossRef
A comparison of resveratrol and other polyphenolic compounds on Notch activation and endothelial cell activity
Bryce LaFoya, Jordan A. Munroe, Allan R. Albig, Myon-Hee Lee
PLOS ONE.2019; 14(1): e0210607. CrossRef
Resveratrol-Induced Temporal Variation in the Mechanical Properties of MCF-7 Breast Cancer Cells Investigated by Atomic Force Microscopy
Jagoba Iturri, Andreas Weber, Alberto Moreno-Cencerrado, Maria dM Vivanco, Rafael Benítez, Stefano Leporatti, José Luis Toca-Herrera
International Journal of Molecular Sciences.2019; 20(13): 3275. CrossRef
Effect of Fermented Platycodon grandiflorum Extract on Cell Proliferation and Migration in Bovine Aortic Endothelial Cells
Woosoung Choi, Jina Song, Mi-Hyeon Park, Heui Jong Yu, Heonyong Park
Journal of Life Science.2016; 26(1): 59. CrossRef
Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells
RUBICELI MEDINA-AGUILAR, LAURENCE A. MARCHAT, ELENA ARECHAGA OCAMPO, PATRICIO GARIGLIO, JAIME GARCÍA MENA, NICOLÁS VILLEGAS SEPÚLVEDA, MACARIO MARTÍNEZ CASTILLO, CÉSAR LÓPEZ-CAMARILLO
Oncology Reports.2016; 35(6): 3696. CrossRef
Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells
Tomohiko Fukuda, Katsutoshi Oda, Osamu Wada-Hiraike, Kenbun Sone, Kanako Inaba, Yuji Ikeda, Chinami Makii, Aki Miyasaka, Tomoko Kashiyama, Michihiro Tanikawa, Takahide Arimoto, Tetsu Yano, Kei Kawana, Yutaka Osuga, Tomoyuki Fujii
Oncology Letters.2016; 12(4): 2560. CrossRef
Apoptotic Effect of Pinosylvin at a High Concentration Regulated by c-Jun N-Terminal Kinase in Bovine Aortic Endothelial Cells
Jina Song, Jinsun Park, Eunsil Jeong, A-Young So, Jaeho Pyee, Heonyong Park
Journal of Life Science.2015; 25(4): 416. CrossRef
Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis
Jiening Dun, Xueyan Chen, Haixia Gao, Yan Zhang, Huajun Zhang, Yongjian Zhang
Experimental Biology and Medicine.2015; 240(12): 1672. CrossRef
Pinosylvin at a high concentration induces AMPK-mediated autophagy for preventing necrosis in bovine aortic endothelial cells
Jinsun Park, Jaeho Pyee, Heonyong Park
Canadian Journal of Physiology and Pharmacology.2014; 92(12): 993. CrossRef
Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-α-dependent pathway
Arif Yurdagul, James J. Kleinedler, Marshall C. McInnis, Alok R. Khandelwal, Allyson L. Spence, A. Wayne Orr, Tammy R. Dugas
American Journal of Physiology-Heart and Circulatory Physiology.2014; 306(6): H797. CrossRef
Protective Effects of Resveratrol on TNF-α-Induced Endothelial Cytotoxicity in Baboon Femoral Arterial Endothelial Cells
Juan Xiao, Jun Song, Vida Hodara, Allen Ford, Xing Li Wang, Qiang Shi, Li Chen, John L. VandeBerg
Journal of Diabetes Research.2013; 2013: 1. CrossRef
Synergistic anti-proliferative effect of resveratrol and etoposide on human hepatocellular and colon cancer cell lines
Fatemehsadat Amiri, Amir-Hassan Zarnani, Hamid Zand, Fariba Koohdani, Mahmood Jeddi-Tehrani, Mohammadreza Vafa
European Journal of Pharmacology.2013; 718(1-3): 34. CrossRef
Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity
Vittorio Calabrese, Carolin Cornelius, Albena T. Dinkova-Kostova, Ivo Iavicoli, Rosanna Di Paola, Aleardo Koverech, Salvatore Cuzzocrea, Enrico Rizzarelli, Edward J. Calabrese
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2012; 1822(5): 753. CrossRef
Ameliorative Effects of Resveratrol on Acute Ovarian Toxicity Induced by Total Body Irradiation in Young Adult Rats
Yavuz Simsek, Simay Gurocak, Yusuf Turkoz, Nusret Akpolat, Onder Celik, Ali Ozer, Ercan Yılmaz, Ugur Turhan, Fatma Ozyalin
Journal of Pediatric and Adolescent Gynecology.2012; 25(4): 262. CrossRef
Resveratrol Exerts Dosage and Duration Dependent Effect on Human Mesenchymal Stem Cell Development
Lindsay Peltz, Jessica Gomez, Maribel Marquez, Frances Alencastro, Negar Atashpanjeh, Tara Quang, Thuy Bach, Yuanxiang Zhao, Antonio Paolo Beltrami
PLoS ONE.2012; 7(5): e37162. CrossRef
Resveratrol reduces oxidative stress and cell death and increases mitochondrial antioxidants and XIAP in PC6.3-cells
Minna Kairisalo, Alessandra Bonomo, Alise Hyrskyluoto, Giuseppa Mudò, Natale Belluardo, Laura Korhonen, Dan Lindholm
Neuroscience Letters.2011; 488(3): 263. CrossRef
Effect of resveratrol on endothelial cell function: Molecular mechanisms
Christoph A. Schmitt, Elke H. Heiss, Verena M. Dirsch
BioFactors.2010; 36(5): 342. CrossRef
Dose-Dependency of Resveratrol in Providing Health Benefits
Subhendu Mukherjee, Jocelyn I. Dudley, Dipak K. Das
Dose-Response.2010;[Epub] CrossRef
Resveratrol commonly displays hormesis: Occurrence and biomedical significance
Edward J Calabrese, Mark P Mattson, Vittorio Calabrese
Human & Experimental Toxicology.2010; 29(12): 980. CrossRef
Biochemical characterization of the lipid-binding properties of a broccoli cuticular wax-associated protein, WAX9D, and its application
Sun-Young Ahn, Jong-Min Kim, Jae-Ho Pyee, Heon-Yong Park
BMB Reports .2009; 42(6): 367. CrossRef

10,003 View
59 Download
21 Crossref

Phase II Study of Irinotecan, 5-Fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as First-line Therapy: Young-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn; Cancer Res Treat. 2004;36(4):235-239. Published online August 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.4.235

Abstract PDF PubReader ePub

Background

The purpose of this study was to assess the efficacy and toxicity of biweekly irinotecan plus 5-fluorouracil (FU) and leucovorin (LV) in patients with relapsed or metastatic colorectal cancer.

Materials and Methods

Between March 2002 and May 2004, 24 patients with histologically confirmed relapsed or metastatic colorectal cancer were enrolled in this study. One chemotherapy cycle consisted of irinotecan 180 mg/m² on days 1 and 15; 5-FU 400 mg/m² bolus IV with 600 mg/m² by a 22 hour intravenous infusion on days 1, 2, 15 and 16; and leucovorin 20 mg/m² on days 1, 2, 15 and 16, every 4 weeks.

Results

The median age of the 24 was 57.5 years (range, 38~69). Their metastatic sites included: the liver (62.5%), lung (20.8%), peritoneum (16.7%), lymph node (12.5%), ovary (8.3%) and pelvis/vagina (8.3%). Twenty-two patients were evaluable for a response. Six and 7 patients achieved partial responses and stable diseases, respectively. The overall response rate was 27.3% (95% Confidence interval; 10.3~44.5%). The median follow-up duration for surviving patients was 14.7 months (range, 1.7~26.5). Median overall survival (OS) and 1-year OS rates were 19 months and 86.3%, respectively. Median response duration and median progression free survival were 7.47 and 5.57 months, respectively. A total of 83 cycles (median 4 cycles) were administered. The main non-hematologic toxicities were nausea/vomiting (44.5%/18.1%) and diarrhea (8.4%). The most common hematologic toxicity was NCI grade I/II anemia (31.3%) and grade I/II neutropenia was 10.8%. There was no life-threatening toxicity.

Conclusion

The results suggested that irinotecan, 5-FU and leucovorin combination chemotherapy in a biweekly schedule is a practical and tolerable treatment option in patients with advanced colorectal cancer.

Citations

Citations to this article as recorded by

A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI
Kyu-Pyo Kim, Yong Sang Hong, Jae-Lyun Lee, Kyun Seop Bae, Ho-Sook Kim, Jae-Gook Shin, Jung Shin Lee, Tae Won Kim
Oncology.2015; 88(3): 164. CrossRef
Effect of an Irinotencan, 5-Fluorouracil, and Leucovorin Combination Chemotherapy (FOLFIRI) in Metastatic Colorectal Cancer
Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek
Journal of the Korean Society of Coloproctology.2007; 23(5): 333. CrossRef
A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer
Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Cancer Research and Treatment.2006; 38(2): 72. CrossRef
Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer
Myung-Ah Lee, Jae-Ho Byun, Byoung-Young Shim, In-Sook Woo, Jin-Hyung Kang, Young Seon Hong, Kyung Shik Lee, Myung Gyu Choi, Suk Kyun Chang, Seong Taek Oh, Sung Il Choi, Doo Suk Lee
The Korean Journal of Internal Medicine.2005; 20(3): 205. CrossRef
Responsiveness of CPT-11 in Respect to hMLH1 and hMSH2 Protein Expression in the Primary Colorectal Cancer
In Ja Park, Hee Cheol Kim, Chang Sik Yu, Heung Moon Chang, Jea Hwan Lee, Jong Hoon Kim, Tae Won Kim, Jung Sun Kim, Jin Cheon Kim
Cancer Research and Treatment.2004; 36(6): 360. CrossRef

8,560 View
57 Download
5 Crossref

The Role of E-cadherin/β-catenin Complex and Cyclin D1 in Head and Neck Squamous Cell Carcinoma: Nam Yong Do, Sung Yong Park, Sung Chul Lim; Cancer Res Treat. 2004;36(1):72-78. Published online February 29, 2004; DOI: https://doi.org/10.4143/crt.2004.36.1.72

Abstract PDF PubReader ePub

Purpose

To determine the relationship between expression pattern of E-cadherin, β-catenin and cyclin D1, and clinicopathologic parameters in patients with head and neck squamous cell carcinomas (HNSCC).

Materials and Methods

The authors evaluated the immunohistochemical expression pattern of E-cadherin, β-catenin in relationship with cyclin D1 overexpression, degree of histologic differentiation, clinical stage, and nodal status in 146 head and neck squamous cell carcinomas (HNSCC). The authors also evaluated the expression of E-cadherin/β-catenin complex, E-cadherin/cyclin D1, and β-catenin/cyclin D1 double staining with confocal laser scanning microscope.

Results

Aberrant expressions in 78% of E-cadherin, 77% of β-catenin, and 69% of cyclin D1 in the HNSCC were observed. There was correlation of aberrant expression of E-cadherin and nodal status. Cyclin D1 overexpression was also correlated to clinical stage and nodal status. Significant relation was observed between E-cadherin and β-catenin expression patterns. Co-expression of E-cadherin and β-catenin was significantly detected. However, there was no correlation of cyclin D1 overexpression with E-cadherin or β-catenin expression patterns.

Conclusion

These results suggest that aberrant expression of E-cadherin, E-cadherin/β-catenin complex, and cyclin D1 may be involved in clinical stage and/or nodal status, and analysis of the pattern of E-cadherin, cyclin D1, and E-cadherin/β-catenin complex may be good prognostic marker of HNSCC.

Citations

Citations to this article as recorded by

Pilomatrix carcinoma of the right postauricular region: A case report and literature review
Shabiah Martin, Jana DeJesus, Ann Jacob, Teah Qvavadze, Claudio Guerrieri, Rachel Hudacko, Thaddeus Boucree
International Journal of Surgery Case Reports.2019; 65: 284. CrossRef
Role of E-cadherin and cyclin D1 as predictive markers of aggression and clonal expansion in head and neck squamous cell carcinoma
Khushdeep Shergill, Arijit Sen, Hari Janardanan Pillai
Journal of the Korean Association of Oral and Maxillofacial Surgeons.2018; 44(4): 182. CrossRef
Prognostic Significance of Cyclin D1 and E-cadherin Expression in Laryngeal Squamous Cell Carcinoma
Rehab Allah Ahmed, Abd El-Aty Shawky, Rasha Hamdy Hamed
Pathology & Oncology Research.2014; 20(3): 625. CrossRef

8,554 View
49 Download
3 Crossref

A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane: Jun Yong Park, Chul Kim, Joo Hyuk Sohn, Yong Tae Kim, Sun Young Rha, Woo Ick Jang, Gwi Eon Kim, Hyun Cheol Chung; Cancer Res Treat. 2002;34(4):274-279. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.274

Abstract PDF

We performed a phase II trial to evaluate the efficacy and the safety of gemcitabine monotherapy, a pyrimidine antimetabolite, in patients, who had previously failed anthracycline and taxane-based chemotherapy for the treatment of metastatic breast cancer.
MATERIALS AND METHODS
Twenty-one patients with metastatic breast cancer, which was unresponsive to previous chemotherapy, were entered into this study. Gemcitabine was administered at 850 mg/m2, as a 60- minute intravenous infusion on days 1, 8 and 15. This regimen was repeated every 28 days with G-CSF support, but without dose reduction.
RESULTS
Objective responses were seen in 6 of the 20 patients who were able to be evaluated (1 complete response and 5 partial responses), with an objective response rate of 30%. The median time to progression was 5 (1~20) months, and the median overall survival duration was 11 (2~21) months. The actual dose intensity was 566.7 mg/m2/wk (range; 340~637.5 mg/m2/wk) and the relative dose intensity was 0.89 (range; 0.40~1.00). Toxicity was mainly hematological. Toxicities included: grade 3 neutropenia in 20% and anemia in 5%. Grades 3 and 4 thrombocytopenia occurred in 15% of the patients.
CONCLUSION
Gemcitabine monotherapy is an effective and safe treatment for refractory breast cancer patients heavily treated with the anthracycline and taxane- based regimen.

Citations

Citations to this article as recorded by

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer
Clinton Yam, Rashmi K. Murthy, Vicente Valero, Janio Szklaruk, Girish S. Shroff, Carol J. Stalzer, Aman U. Buzdar, James L. Murray, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun
Investigational New Drugs.2018; 36(2): 299. CrossRef
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
Woo Sun Kwon, Sun Young Rha, Yeon Ho Choi, Jung Ok Lee, Kyu Hyun Park, Jae Joon Jung, Tae Soo Kim, Hei-Cheul Jeung, Hyun Cheol Chung
Pharmacogenetics and Genomics.2006; 16(6): 429. CrossRef
Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients
Min Kyoung Kim, Sung-Bae Kim, Jin Hee Ahn, Soon Im Lee, Sei-Hyun Ahn, Byung Ho Son, Gyungyub Gong, Hak-Hee Kim, Jung-Shin Lee, Yoon-Koo Kang, Woo Kun Kim
Cancer Research and Treatment.2006; 38(4): 206. CrossRef
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
Sun Young Rha, Yong Hwa Moon, Hei Chul Jeung, Yong Tae Kim, Joo Hyuk Sohn, Woo Ick Yang, Chang Ok Suh, Gwi Eon Kim, Jae Kyung Roh, Hyun Cheol Chung
Breast Cancer Research and Treatment.2005; 90(3): 215. CrossRef

4,710 View
35 Download
4 Crossref

The Effects of Irradiation on Lung Function in Patients with Lung Cancer: Kyung Hee Gang, Jae Yong Park, Kyung Rok Kim, Po Hee Chae, Nack Cheon Bae, Seung Ick Cha, Chang Ho Kim, Tae Hoon Jung; Cancer Res Treat. 2002;34(4):264-267. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.264

Abstract PDF: This study was performed to assist in the prediction of the clinical tolerance of patients with lung cancer to irradiation.
MATERIALS AND METHODS
The changes in lung function of 26 patients with lung carcinomas, who had received radiation with curative intent, or postoperative adjuvant radiotherapy, were prospectively studied. Their pulmonary function tests were conducted at presentation, and then at 2 weeks, 2 months, and 6 months, following radiotherapy.
RESULTS
When the parameters of postirradiation pulmonary functions (2 weeks, 2 months and 6 months) were compared with the preirradiation baseline data, there was a statistically significant decrease in FEF25~75% at 2 months, but the rest of the parameters showed no significant change following irradiation. However, when the baseline lung function was compared with the lung function at the lowest FVC, in patients with curative radiotherapy, there was a statistically significant decrease of about 10% in the FEV1 and DLCO.
CONCLUSION
Preirradiation assessment of pulmonary functions, particularly the FEV1 and DLCO will be useful for the prediction of the clinical tolerance to irradiation.

4,302 View
18 Download

Review Article

Genetic Susceptibility to Lung Cancer in Koreans: Jae Yong Park; Cancer Res Treat. 2002;34(1):8-12. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.8

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Tobacco, Genetic Susceptibility and Lung cancer
Ravindran Ankathil
Tobacco Use Insights.2010;[Epub] CrossRef

3,960 View
20 Download
1 Crossref

Original Articles

The Role of Transbronchial Needle Aspiration for Diagnosis of Bronchogenic Carcinoma: Kwan Young Kim, Jae Yong Park, Seung Ick Cha, Ki Su Park, Tae Kyong Kang, Chang Ho Kim, Tae Hoon Jung; J Korean Cancer Assoc. 2000;32(1):93-99.

Abstract PDF: PURPOSE
Transbronchial needle aspiration (TBNA) has been used for the diagnosis and staging of bronchogenic carcinoma through the flexible bronchoscope. The aim of this study was to investigate the diagnostic role of TBNA for bronchogenic carcinoma.
MATERIALS AND METHODS
TBNA was performed in 34 patients with suspected bron- chogenic carcinoma. We analyzed diagnostic rate of TBNA m 28 patients who were ulti- mately diagnosed as bronchogenic carcinoma.
RESULTS
In 12 of 28 patients, TBNA was performed for endobronchial lesions with a type of infiltration, nodular infiltration or compression. The diagnostic rate was 75%. Addition of TBNA to bronchial washing, brush, and biopsy increased the diagnostic rate from 58% to 80%. In 16 patients with peripheral tumor and mediastinal lymphadenopathy, TBNA was performed for mediastinal lymph nodes. The diagnostic rate was 62.5%, and was positively correlated with the size of lymph nodes. There was no significant complications related to TBNA.
CONCLUSION
TBNA was a safe and effective procedure for the diagnosis of bronchogenic carcinoma in selected patients.

3,184 View
19 Download

Differences of Diagnostic Rate According to Technique of Bronchial Brush in the Diagnosis of Lung Cancer: Seung Ick Cha, Jae Yong Park, Jun Hee Won, Tae Kyong Kang, Ki Sun Park, Chang Ho Kim, Tae Hoon Jung, Tae In Park, Yoon Kyong son; J Korean Cancer Assoc. 1999;31(4):686-691.

Abstract PDF: PURPOSE
Brush cytology is one of useful methods for establishing a diagnosis of lung cancer. There are two methods of retrieving the specimen of brush cytology. One is to withdraw the brush through the working channel of the bronchoscope (withdrawn brush) and the other is to withdraw the brush and bronchoscope as a unit, with brush remaining protruded through the distal tip of the bronchoscope (nonwithdrawn brush). We tried to compare two methods in the cellularity of the specimen and the diagnosis of lung cancer.
MATERIALS AND METHODS
Thirty-one patients with suspected lung cancer were studied prospectively. The sequence of sampling (withdrawn or nonwithdrawn brush) was assigned randomly. The specimens were interpreted by two cytopathologists about cellularity (1-4) and presence of recognizable malignant cells.
RESULTS
Cellularity was significantly greater for nonwithdrawn brush (p<0.05). There was no significant difference of diagnostic rate between both methods in the diagnosis of lung cancer.
CONCLUSION
Withdrawing the brush through the bronchoscope decreases the cellularity, but it does not affect the diagnostic rate for lung cancer.

2,411 View
14 Download

Combined Therapy of Gene Therapy using the Herpes Simplex Virus Thymidine Kinase, and Retinoic Acid: Jae Yong Park, Steven M Albelda; J Korean Cancer Assoc. 1997;29(2):321-331.

Abstract PDF: PURPOSE
Metabolic cooperation via gap junctional intercellular communication (GJIC) is an important mechanism of the bystander effect in gene therapy using the Herpes Simplex Virus thymidine kinase/ganciclovir (HSVtk/GCV) "prodrug" system. Since retinoids have been reported to increase GJIC by induction of connexin expression, we hypothesized that these compound could be used to augment the HSVtk/GCV bystander effect.
MATERIALS AND METHODS
We transferred HSVtk gene to AB12 cell line that express connexin43 as a component of gap junction. We examined the effects of retinoic acid (RA) on GJIC utilizing a functional double-dye transfer study. To evaluate the bystander effect in vivo, a murine subcutaneous tumor model was established. Before proceeding with comparisons of HSVtk/GCV mediated bystander cell killing, we evaluated the effects of RA on flank tumor growth in order to rule out a potential antitumor effect of RA alone. Then we determined the effects of retinoic acid on bystander-mediated cell killing in an animal model.
RESULTS
Addition of all-trans retinoic acid increased GJIC in AB12 cell line and was associated with more efficient GCV induced bystander killing in animal model. HSVtk transduced tumors in mice treated with the combination of GCV and retinoids were significantly smaller than those treated with GCV or retinoids alone.
CONCLUSION
These results provide evidence that retinoids can augment the efficiency of cell killing with the HSVtk/GCV system by enhancing bystander effects and may thus be a promising new approach to improve response in gene therapy utilizing the HSVtk/GCV system to treat tumors.

2,400 View
14 Download

Thermal Distribution and Development of RF Hyperthermia for Cancer Treatment: Sung Sil Chu, Gwi Eon Kim, John J. K. Loh, Byung Soo Kim, Min Yong Park, Sung Wha Yang, Dong Kun Jung; J Korean Cancer Assoc. 1986;18(2):183-194.

Abstract PDF: The biological effects for the use of hyperthermia to treat malignant tumors has been well studied and encouraging clinical results have been reported. However, the engineering and technical aspects of hyperthermia for the deep-seated tumors has not been satisfactory. We have developed the RF capacitive hyperthermia device (Greenytherm-GY 8) by coopera- tion with Yonsei Cancer Center and Green Cross Medical Corporation. It was composed with 8-10 MHz RF generator, capacitive electrode, matching system, cooling system, tem- perature measuring thermocouples and control PC computer. We have measured the tempe- rature and thermal distribution in agar phantom, animals and human tumors. This RF hyperthermia device could be applied for clinical trials as result of following studies. 1) The generating power could be varied to 700-1500 W 2) The Radio-frequency for capacitive heating could be produced to 8-10 MHz 3) It was possible to contral the depth heating from skin by regulation the cooling tem- perature of bolus and choosing properly size electrodes. 4) Deep seated tumors (5-10 cm depth) might be heated to therapeutic temperature 40- 43' C. 5) Side effects and hot feeling on skin could be significantly reduced by cooling bolus and electric matching.

2,428 View
24 Download

First
Prev
Page of 1
Next
Last

Search